Y Intercept Hong Kong Ltd Invests $718,000 in BioNTech SE (NASDAQ:BNTX)

Y Intercept Hong Kong Ltd purchased a new stake in BioNTech SE (NASDAQ:BNTX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 6,046 shares of the company’s stock, valued at approximately $718,000.

A number of other institutional investors have also recently modified their holdings of the business. Planning Capital Management Corp raised its position in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after acquiring an additional 450 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of BioNTech in the third quarter valued at about $210,000. Finally, Probity Advisors Inc. purchased a new stake in BioNTech during the third quarter worth about $216,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BNTX. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. UBS Group boosted their target price on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. TD Cowen cut their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. Finally, The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.76.

BioNTech Stock Performance

BioNTech stock opened at $120.38 on Friday. The stock has a fifty day moving average price of $113.86 and a 200 day moving average price of $100.34. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market capitalization of $28.62 billion, a P/E ratio of -57.32 and a beta of 0.22. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period in the prior year, the firm posted $0.73 EPS. The company’s revenue was up 38.9% on a year-over-year basis. Equities research analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.